Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma

Tarek H. Mouhieddine; Julia Hieulle; Erin Moshier; Shambavi Richard; Joshua Richter; Hearn Jay Cho; Samir Parekh; Bart Barlogie; Ajai Chari; Sundar Jagannath; Deepu Madduri

doi:10.1016/j.clml.2021.09.004

Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma

Tarek H. Mouhieddine, Julia Hieulle, Erin Moshier, Shambavi Richard, Joshua Richter, Hearn Jay Cho, Samir Parekh, Bart Barlogie, Ajai Chari, Sundar Jagannath, Deepu Madduri

Research output: Contribution to journal › Editorial

2 Scopus citations

Original language	English
Pages (from-to)	129-132
Number of pages	4
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	22
Issue number	2
DOIs	https://doi.org/10.1016/j.clml.2021.09.004
State	Published - Feb 2022

Keywords

Low dose chemotherapy
Metronomic therapy
Penta refractory myeloma

Access to Document

10.1016/j.clml.2021.09.004

Cite this

@article{8b9a5d9c8ee34219a63e6c68f050448d,

title = "Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma",

keywords = "Low dose chemotherapy, Metronomic therapy, Penta refractory myeloma",

author = "Mouhieddine, {Tarek H.} and Julia Hieulle and Erin Moshier and Shambavi Richard and Joshua Richter and Cho, {Hearn Jay} and Samir Parekh and Bart Barlogie and Ajai Chari and Sundar Jagannath and Deepu Madduri",

note = "Funding Information: J.R. received speaking fees from Celgene and Janssen, and advisory board and consulting fees from Celgene, Janssen, Bristol Myers Squibb, Oncopeptides, Adaptive Biotechnologies, X4 Pharmaceuticals, Karyopharm and Antegene. H.J.C. is an employee of the Multiple Myeloma Research Foundation, received commercial research support from Agenus Inc. and Genentech Roche, and compensation for consulting/advisory boards from Genentech Roche, Celgene, Bristol- Myers Squibb, and GlaxoSmithKline. S.P. received consulting fees from Foundation Medicine and research funding from Celgene and Karyopharm. A.C. received honoraria from Amgen, Antengene, Celgene, Janssen, Karyopharm, Millennium/Takeda, Novartis Pharmaceuticals, Oncopeptides, Sanofi and received research funding from Amgen, Celgene, Janssen, Millennium/Takeda, Novartis Pharmaceuticals, Pharmacyclics. S. J. received advisory board fees and consulting fees from Celgene, Bristol‐Myers Squibb, Janssen Pharmaceuticals and Merck. D.M. is an employee of Janssen and received consulting fees from Celgene, AbbVie, Takeda and Foundation Medicine. T.H.M., J.H., E.M. and B.B. declare no potential conflict of interest.",

year = "2022",

month = feb,

doi = "10.1016/j.clml.2021.09.004",

language = "English",

volume = "22",

pages = "129--132",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma

AU - Mouhieddine, Tarek H.

AU - Hieulle, Julia

AU - Moshier, Erin

AU - Richard, Shambavi

AU - Richter, Joshua

AU - Cho, Hearn Jay

AU - Parekh, Samir

AU - Barlogie, Bart

AU - Chari, Ajai

AU - Jagannath, Sundar

AU - Madduri, Deepu

N1 - Funding Information: J.R. received speaking fees from Celgene and Janssen, and advisory board and consulting fees from Celgene, Janssen, Bristol Myers Squibb, Oncopeptides, Adaptive Biotechnologies, X4 Pharmaceuticals, Karyopharm and Antegene. H.J.C. is an employee of the Multiple Myeloma Research Foundation, received commercial research support from Agenus Inc. and Genentech Roche, and compensation for consulting/advisory boards from Genentech Roche, Celgene, Bristol- Myers Squibb, and GlaxoSmithKline. S.P. received consulting fees from Foundation Medicine and research funding from Celgene and Karyopharm. A.C. received honoraria from Amgen, Antengene, Celgene, Janssen, Karyopharm, Millennium/Takeda, Novartis Pharmaceuticals, Oncopeptides, Sanofi and received research funding from Amgen, Celgene, Janssen, Millennium/Takeda, Novartis Pharmaceuticals, Pharmacyclics. S. J. received advisory board fees and consulting fees from Celgene, Bristol‐Myers Squibb, Janssen Pharmaceuticals and Merck. D.M. is an employee of Janssen and received consulting fees from Celgene, AbbVie, Takeda and Foundation Medicine. T.H.M., J.H., E.M. and B.B. declare no potential conflict of interest.

PY - 2022/2

Y1 - 2022/2

KW - Low dose chemotherapy

KW - Metronomic therapy

KW - Penta refractory myeloma

UR - http://www.scopus.com/inward/record.url?scp=85117161663&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2021.09.004

DO - 10.1016/j.clml.2021.09.004

M3 - Editorial

C2 - 34670732

AN - SCOPUS:85117161663

SN - 2152-2650

VL - 22

SP - 129

EP - 132

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 2

ER -